The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease

키워드

참고문헌 (123)

1. Falagas ME, "Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid : a review of the available evidence", Int J Antimicrob Agents, 30, pp.477~486 (2007)
2. Rahier JF, "Vaccinations in patients with immune-mediated inflammatory diseases", Rheumatology(Oxford), 49, pp.1815~1827 (2010)
3. Bosch X, "Infections in systemic lupus erythematosus : a prospective and controlled study of 110 patients", Lupus, 15, pp.584~589 (2006)
4. Doran MF, "Predictors of infection in rheumatoid arthritis", Arthritis Rheum, 46, pp.2294~2300 (2002)
5. Martin-Mola E, "Infectious complications of biologic agents", Rheum Dis Clin North Am, 35, pp.183~199 (2009)
6. Furst DE, "The risk of infections with biologic therapies for rheumatoid arthritis", Semin Arthritis Rheum, 39, pp.327~346 (2010)
7. Glück T, "Vaccination in patients with chronic rheumatic or autoimmune diseases", Clin Infect Dis, 46, pp.1459~1465 (2008)
8. Hmamouchi I, "Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis : data from the international COMORA cohort", Vaccine, 33, pp.1446~1452 (2015)
9. Kim SY, "Handbook for clinical practice guideline developer, version 1.0", National Evidence-based Healthcare Collaborating Agency, 1~428 (2015)
10. Nohynek H, "AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland", PLoS One, 7, pp.e33536~ (2012)
11. Partinen M, "Narcolepsy as an autoimmune disease : the role of H1N1 infection and vaccination", Lancet Neurol, 13, pp.600~613 (2014)
12. Mantadakis E, "Thrombocytopenic purpura after measles-mumps-rubella vaccination : a systematic review of the literature and guidance for management", J Pediatr, 156, pp.623~628 (2010)
13. Andrews N, "A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark", Vaccine, 30, pp.3042~3046 (2012)
14. Miller E, "Idiopathic thrombocytopenic purpura and MMR vaccine", Arch Dis Child, 84, pp.227~229 (2001)
15. Israeli E, "Adjuvants and autoimmunity", Lupus, 18, pp.1217~1225 (2009)
16. Wraith DC, "Vaccination and autoimmune disease: what is the evidence?", Lancet, 362, pp.1659~1666 (2003)
17. Perricone C, "Autoimmune", inflammatory syndrome induced by adjuvants(ASIA)2013 : Unveiling the pathogenic, clinical and diagnostic aspects, 2013, pp.47, 1~16
18. Louie JS, "Clinical and antibody responses after influenza immunization in systemic lupus erythematosus", Ann Intern Med, 88, pp.790~792 (1978)
19. Zycinska K, "Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis", J Physiol Pharmacol, 58(Suppl 5), pp.819~828 (2007)
20. Ristow SC, "Influenza vaccination of patients with systemic lupus erythematosus", Ann Intern Med, 88, pp.786~789 (1978)
21. Rubin LG, "2013 IDSA clinical practice guideline for vaccination of the immunocompromised host", Clin Infect Dis, 58, pp.309~318 (2014)
22. Cordeiro I, "Recommendations for vaccination in adult patients with systemic inflammatory rheumatic diseases from the Portuguese Society of Rheumatology", Acta Reumatol Port, 41, pp.112~130 (2016)
23. van Assen S, "EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases", Ann Rheum Dis, 70, pp.414~422 (2011)
24. Singh JA, "2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 68, pp.1~26 (2016)
25. Bühler S, "Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases", Swiss Med Wkly, 145, pp.w14159~ (2015)
26. Bombardier C, "Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs : part II safety", J Rheumatol, 39, pp.1583~1602 (2012)
27. Ledingham J, "Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)", Rheumatology (Oxford), 44, pp.157~163 (2005)
28. Pham T, "Rituximab (MabThera) therapy and safety management. Clinical tool guide", Joint Bone Spine, 75(Suppl 1), pp.S1~S99 (2008)
29. Pham T, "Tocilizumab: therapy and safety management", Joint Bone Spine, 77(Suppl 1), pp.S3~S100 (2010)
30. Pham T, "Abatacept therapy and safety management", Joint Bone Spine, 76(Suppl 1), pp.S3~S55 (2009)
31. Pham T, "Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française De Rhumatologie, SFR)", Joint Bone Spine, 72(Suppl 1), pp.S1~S58 (2005)
32. Kapetanovic MC, "Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis", Rheumatology(Oxford), 45, pp.106~111 (2006)
33. Gelinck LBS, "Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine", Vaccine, 26, pp.3528~3533 (2008)
34. Kaine JL, "Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab", J Rheumatol, 34, pp.272~279 (2007)
35. Ribeiro AC, "Abatacept and reduced immune response to pandemic 2009 influenza A", H1N1 vaccination in patients with rheumatoid arthritis, 2013, pp.65, 476~480
36. Bingham CO 3rd, "Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab : results of a randomised controlled trial(VISARA)", Ann Rheum Dis, 74, pp.818~822 (2015)
37. Hua C, "Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis", Arthritis Care Res (Hoboken), 66, pp.1016~1026 (2014)
38. Morel J, "Vaccinations in adults with chronic inflammatory joint disease : Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs", Joint Bone Spine, 83, pp.135~141 (2016)
39. Brenol CV, "Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America", J Clin Rheumatol, 24, pp.138~147 (2018)
40. Tanrıöer MD, "Vaccination recommendations for adult patients with rheumatic diseases", Eur J Rheumatol, 3, pp.29~35 (2016)
41. Staples JE, "Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 59(RR-7), pp.1~27 (2010)
42. Potter J, "Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients", J Infect Dis, 175, pp.1~6 (1997)
43. Carman WF, "Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care : a randomised controlled trial", Lancet, 355, pp.93~97 (2000)
44. Babcock HM, "Mandatory influenza vaccination of health care workers : translating policy to practice", Clin Infect Dis, 50, pp.459~464 (2010)
45. Pearson ML, "Influenza vaccination of health-care personnel : recommendations of the Healthcare Infection Control Practices Advisory Committee(HICPAC)and the Advisory Committee on Immunization Practices(ACIP)", MMWR Recomm Rep, 55, pp.1~16 (2006)
46. Marin M, "Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 56, pp.1~40 (2007)
47. Sharrar RG, "The postmarketing safety profile of varicella vaccine", Vaccine, 19, pp.916~923 (2000)
48. Grossberg R, "Secondary transmission of varicella vaccine virus in a chronic care facility for children", J Pediatr, 148, pp.842~844 (2006)
49. Nichol KL, "Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens", Arch Intern Med, 158, pp.1769~1776 (1998)
50. Blumentals WA, "Rheumatoid arthritis and the incidence of influenza and influenza-related complications : a retrospective cohort study", BMC Musculoskelet Disord, 13, pp.158~ (2012)
51. Chalmers A, "Immunization of patients with rheumatoid arthritis against influenza : a study of vaccine safety and immunogenicity", J Rheumatol, 21, pp.1203~1206 (1994)
52. Del Porto F, "Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity", Vaccine, 24, pp.3217~3223 (2006)
53. Denman EJ, "Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis", Ann Rheum Dis, 29, pp.220~231 (1970)
54. Elkayam O, "The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis", Semin Arthritis Rheum, 39, pp.442~447 (2010)
55. Fomin I, "Vaccination against influenza in rheumatoid arthritis : the effect of disease modifying drugs, including TNF alpha blockers", Ann Rheum Dis, 65, pp.191~194 (2006)
56. Gelinck LB, "The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination", Ann Rheum Dis, 67, pp.713~716 (2008)
57. Herron A, "Influenza vaccination in patients with rheumatic diseases. Safety and efficacy", JAMA, 242, pp.53~56 (1979)
58. Kubota T, "Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis", Mod Rheumatol, 17, pp.531~533 (2007)
59. Nii T, "Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers", Mod Rheumatol, 19, pp.216~218 (2009)
60. Turner-Stokes L, "In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases", Ann Rheum Dis, 47, pp.532~535 (1988)
61. van Assen S, "Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab", Arthritis Rheum, 62, pp.75~81 (2010)
62. Williams GW, "Influenza immunization in systemic lupus eruthematosus. A double-blind trial", Ann Intern Med, 88, pp.729~734 (1978)
63. Holvast B, "Influenza vaccination in systemic lupus erythematosus: safe and protective?", Autoimmun Rev, 6, pp.300~305 (2007)
64. Mercado U, "Influenza vaccination of patients with systemic lupus erythematosus", Rev Invest Clin, 56, pp.16~20 (2004)
65. Wiesik-Szewczyk E, "Anti-influenza vaccination in systemic lupus erythematosus patients : an analysis of specific humoral response and vaccination safety", Clin Rheumatol, 29, pp.605~613 (2010)
66. Caza T, "Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus", Int Rev Immunol, 33, pp.330~363 (2014)
67. Borba EF, "Influenza A", H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?, 2012, pp.51, 1061~1069
68. Brodman R, "Influenzal vaccine response in systemic lupus erythematosus", Ann Intern Med, 88, pp.735~740 (1978)
69. Pons VG, "Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus", J Med Virol, 4, pp.15~23 (1979)
70. Holvast A, "Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus", Arthritis Rheum, 60, pp.2438~2447 (2009)
71. Setti M, "Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients", Vaccine, 27, pp.3367~3372 (2009)
72. Holvast A, "Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination", Ann Rheum Dis, 68, pp.873~878 (2009)
73. Pasoto SG, "Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome", Vaccine, 31, pp.1793~1798 (2013)
74. Kobashigawa T, "Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort", Scand J Rheumatol, 42, pp.445~450 (2013)
75. Stojanovich L, "Influenza vaccination of patients with systemic lupus erythematosus(SLE)and rheumatoid arthritis(RA)", Clin Dev Immunol, 13, pp.373~375 (2006)
76. Torres A, "Risk factors for community-acquired pneumonia in adults in Europe : a literature review", Thorax, 68, pp.1057~1065 (2013)
77. Rákóczi É, "Pneumococcal vaccination in autoimmune rheumatic diseases", RMD Open, 3, pp.e000484~ (2017)
78. Kashef S, "Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid", Iran J Immunol, 5, pp.181~184 (2008)
79. Karsh J, "Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine : a randomized trial", Arthritis Rheum, 23, pp.1294~1298 (1980)
80. Hesselstrand R, "Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis", Rheumatology(Oxford), 57, pp.625~630 (2018)
81. Nived P, "Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment", BMC Rheumatol, 2, pp.12~ (2018)
82. Grabar S, "Pneumococcal vaccination in patients with systemic lupus erythematosus : a multicenter placebo-controlled randomized double-blind study", Vaccine, 35, pp.4877~4885 (2017)
83. Nived P, "Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy", Vaccine, 35, pp.3639~3646 (2017)
84. Battafarano DF, "Antigen-specific antibody responses in lupus patients following immunization", Arthritis Rheum, 41, pp.1828~1834 (1998)
85. Izumi Y, "The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis : a double-blinded, randomized, placebo-controlled trial", Arthritis Res Ther, 19, pp.15~ (2017)
86. Watad A, "Autoimmune", inflammatory syndrome induced by adjuvants(Shoenfeld's syndrome)-an update, 2017, pp.26, 675~681
87. Hügle T, "Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine", Rheumatology(Oxford), 51, pp.761~762 (2012)
88. Felicetti P, "Spontaneous reports of vasculitis as an adverse event following immunization : a descriptive analysis across three international databases", Vaccine, 34, pp.6634~6640 (2016)
89. Choi MJ, "Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea", Hum Vaccin Immunother, 14, pp.1914~1922 (2018)
90. Russell FM, "Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial", Vaccine, 28, pp.3341~3349 (2010)
91. Tanaka E, "Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors", Hepatol Res, 42, pp.333~339 (2012)
92. Oshima Y, "Association of hepatitis B with antirheumatic drugs : a case-control study", Mod Rheumatol, 23, pp.694~704 (2013)
93. Xuan D, "Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review", Clin Rheumatol, 33, pp.577~586 (2014)
94. Chen MH, "Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment", J Infect Dis, 215, pp.566~573 (2017)
95. Singh JA, "2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Care Res(Hoboken), 68, pp.1~25 (2016)
96. The Korean Society of Infectious Diseases, "Vaccinations for adults" (2012), MIP
97. Intongkam S, "Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and", or biologics therapy, 2019, pp.25, 329~334
98. Lan JL, "Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy", Ann Rheum Dis, 70, pp.1719~1725 (2011)
99. Wang QX, "Significance of anti-HBc alone serological status in clinical practice", Lancet Gastroenterol Hepatol, 2, pp.123~134 (2017)
100. Elkayam O, "Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis", Ann Rheum Dis, 61, pp.623~625 (2002)
101. Kim KA, "Nationwide seropositivity of hepatitis A in Republic of Korea from 2005 to 2014, before and after the outbreak peak in 2009", PLoS One, 12, pp.e0170432~ (2017)
102. Askling HH, "Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis : a prospective, open-label, multi-centre study", Travel Med Infect Dis, 12, pp.134~142 (2014)
103. 이유현, "Prevalence of Human Papilloma Virus Infections and Cervical Cytological Abnormalities among Korean Women with Systemic Lupus Erythematosus", Journal of Korean Medical Science, 25(10), pp.1431~1437 (2010), 대한의학회
104. Tam LS, "Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus : association with human papillomavirus infection", Arthritis Rheum, 50, pp.3619~3625 (2004)
105. Tam LS, "Natural history of cervical papilloma virus infection in systemic lupus erythematosus-a prospective cohort study", J Rheumatol, 37, pp.330~340 (2010)
106. Anderson EJ, "Rotavirus vaccines : viral shedding and risk of transmission", Lancet Infect Dis, 8, pp.642~649 (2008)
107. Mok CC, "Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus : a case-control study", Ann Rheum Dis, 72, pp.659~664 (2013)
108. Slade BA, "Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine", JAMA, 302, pp.750~757 (2009)
109. Nies K, "Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses", Arthritis Rheum, 23, pp.1343~1350 (1980)
110. Bingham CO 3rd, "Immunization responses in rheumatoid arthritis patients treated with rituximab : results from a controlled clinical trial", Arthritis Rheum, 62, pp.64~74 (2010)
111. Tay L, "Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept : a randomized, open-label, parallel group study in healthy subjects", Arthritis Res Ther, 9, pp.R38~ (2007)
112. Abe T, "Immunological reactivity in patients with systemic lupus erythematosus. Humoral antibody and cellular immune responses", Acta Rheumatol Scand, 17, pp.35~46 (1971)
113. Devey ME, "Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus", Clin Exp Immunol, 68, pp.562~569 (1987)
114. Westra J, "Vaccination of patients with autoimmune inflammatory rheumatic diseases", Nat Rev Rheumatol, 11, pp.135~145 (2015)
115. Zhang J, "The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases : a longitudinal observational study", Arthritis Res Ther, 13, pp.R174~ (2011)
116. Zhang J, "Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases", JAMA, 308, pp.43~49 (2012)
117. Yun H, "Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases", J Rheumatol, 44, pp.1083~1087 (2017)
118. Guthridge JM, "Herpes zoster vaccination in SLE : a pilot study of immunogenicity", J Rheumatol, 40, pp.1875~1880 (2013)
119. Dooling KL, "Recommendations of the advisory dommittee on immunization practices for use of herpes zoster vaccines", MMWR Morb Mortal Wkly Rep, 67, pp.103~108 (2018)
120. Shearer WT, "Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts", J Allergy Clin Immunol, 133, pp.961~966 (2014)
121. Heijstek MW, "Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis : a randomized trial", JAMA, 309, pp.2449~2456 (2013)
122. Borte S, "Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept", Rheumatology(Oxford), 48, pp.144~148 (2009)
123. Croce E, "Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation-A systematic review of randomized trials, observational studies and case reports", Vaccine, 35, pp.1216~1226 (2017)